Annovis Bio receives DSMB approval to continue Phase 3 Alzheimer's trial of buntanetap

Annovis Bio, Inc.

DSMB issued positive recommendation on buntanetap safety at 6 months; trial continues without modification.
Phase 3 AD trial is 40% complete; first symptomatic efficacy readout expected in early 2027.
FDA indicated it may accept combined safety data from Alzheimer's and Parkinson's studies in future NDA submission.
6-month safety data in Alzheimer's patients consistent with those observed in Parkinson's patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.